Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Given Consensus Recommendation of “Moderate Buy” by Analysts

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) has earned an average rating of “Moderate Buy” from the eight ratings firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating, three have issued a buy rating and one has issued a strong buy rating on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $46.1667.

A number of analysts recently weighed in on TVRD shares. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, April 10th. BTIG Research reaffirmed a “buy” rating and issued a $15.00 price objective on shares of Tvardi Therapeutics in a report on Wednesday, April 1st. HC Wainwright started coverage on shares of Tvardi Therapeutics in a report on Monday. They issued a “buy” rating and a $9.00 price objective on the stock. Finally, Wall Street Zen cut shares of Tvardi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 4th.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ:TVRD opened at $2.78 on Wednesday. The stock has a market capitalization of $26.08 million, a price-to-earnings ratio of -0.90 and a beta of 0.33. Tvardi Therapeutics has a 1-year low of $2.75 and a 1-year high of $43.65. The company’s fifty day moving average is $3.34 and its two-hundred day moving average is $3.77.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Friday, May 8th. The company reported ($0.73) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). Sell-side analysts expect that Tvardi Therapeutics will post -2.1 EPS for the current fiscal year.

Institutional Trading of Tvardi Therapeutics

Large investors have recently modified their holdings of the company. Goldman Sachs Group Inc. increased its holdings in shares of Tvardi Therapeutics by 37.9% in the 4th quarter. Goldman Sachs Group Inc. now owns 33,131 shares of the company’s stock worth $142,000 after acquiring an additional 9,102 shares during the period. Jane Street Group LLC acquired a new stake in shares of Tvardi Therapeutics in the 4th quarter worth about $204,000. Squarepoint Ops LLC increased its holdings in shares of Tvardi Therapeutics by 534.3% in the 4th quarter. Squarepoint Ops LLC now owns 51,783 shares of the company’s stock worth $223,000 after acquiring an additional 43,619 shares during the period. State Street Corp increased its holdings in shares of Tvardi Therapeutics by 83.7% in the 4th quarter. State Street Corp now owns 115,501 shares of the company’s stock worth $497,000 after acquiring an additional 52,637 shares during the period. Finally, Invesco Ltd. acquired a new position in Tvardi Therapeutics during the 3rd quarter valued at about $3,219,000. Institutional investors and hedge funds own 44.66% of the company’s stock.

About Tvardi Therapeutics

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.